We present here three studies focused on demonstrating the safety of the new vaccine HIPRABOVIS® IBR Marker Live due to the intrinsic characteristics of the double deleted strain (strain CEDDEL) that contains 3 trials. Trial 1: dissemination, shedding and latency; Trial 2: latency, reactivation and re-excretion; Trial 3: abortigenicity and passage through the placenta.